Conversely, donor ASXL1 - and TP53 -CH showed a trend for increased relapse in AML patients treated with allo-HCT. 55 Taken together, the literature suggests that donor CH may influence relapse in allo-HCT; however, the impact likely varies based on multiple factors, such as CH mutation, donor type, and treatments received.
← all excerpts
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action.
1
—
—